Indication: Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic L

An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. coli-derived Asparaginases

Sub-indication: Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic L

Drug Study

Principal Investigator: Ashok Raj, M.D.
Norton Children's Cancer Institute, affiliated with the UofL School of Medicine

Sponsor: Jazz Pharmaceuticals

Search our entire site.